Gujarat Themis secures $58 million private credit for Japanese acquisition – FinSiddhi
Business News

Gujarat Themis secures $58 million private credit for Japanese acquisition

FinSiddhi

Founded in 1981, Gujarat Themis is India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin, according to its website
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

Bombay HC slams FDA for ‘pedantic’ view, clears reopening of 5 MCA eateries

The Maharashtra FDA on Saturday said it would withdraw its order suspending the licences of five restaurants operating on the Mumbai Cricket Association premises, after the Bombay High Court warned of stinging orders against officials for taking a “pedantic instead of pragmatic view” of the situation. A division bench of Acting Chief Justice Ravindra Ghuge…

In 2010, an Irishman began running around the world; four years and roughly 50,000 km later, he finished a global route few runners had ever completed

Tony Mangan began his “World Jog” with the Dublin Marathon in October 2010, then continued running across a route that eventually covered five continents, six deserts and 41 countries. He crossed North and South America, Australia, Asia and Europe before returning to Ireland. Over four years, the journey stretched to roughly 50,000 km and 1,461…

Exide Industries Ltd drops for fifth straight session

Exide Industries Ltd is quoting at Rs 458.8, down 1.39% on the day as on 13:19 IST on the NSE. The stock jumped 14.43% in last one year as compared to a 4.02% slide in NIFTY and a 14.68% spurt in the Nifty Auto index.